Adocia SA (EPA:ADOC)

France flag France · Delayed Price · Currency is EUR
7.43
-0.30 (-3.88%)
Jul 30, 2025, 5:38 PM CET
-3.88%
Market Cap135.50M
Revenue (ttm)12.12M
Net Income (ttm)-9.32M
Shares Out18.24M
EPS (ttm)-0.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume492,491
Average Volume449,964
Open7.50
Previous Close7.73
Day's Range7.34 - 8.05
52-Week Range2.86 - 10.96
Beta0.46
RSI80.91
Earnings DateSep 25, 2025

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and ra... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 75
Stock Exchange Euronext Paris
Ticker Symbol ADOC
Full Company Profile

Financial Performance

In 2024, Adocia's revenue was 12.12 million, an increase of 100.43% compared to the previous year's 6.05 million. Losses were -9.32 million, -55.95% less than in 2023.

Financial Statements